News & Updates

Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.

Individuals with rosacea are at heightened risk of developing subsequent cardiovascular disease, as suggested in a study.

Individuals who had been exposed to upper respiratory tract infection (URTI) and antibiotics as a child are at heightened risks of atopic dermatitis and allergic skin diseases in their young adulthood, as reported in a study.